1.Moreover presence of insulin resistance and diabetes are risk factors for fibrosis progression and nonresponse to antiviral therapy in chronic hepatitis C (CHC).
2.Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.